South Africans are taking to GLP-1 weight loss drugs like ducks to water, with a recent study revealing that one in 20 people is already taking or considering treatments like Wegovy, Ozempic and Mounjaro, reports TimesLIVE.
According to the research by consumer data company Worldpanel by Numerator, about 13% of South Africans fall into this category – but a total of 63% of the population have still never heard of injectable weight loss medications.
“Only 37% of consumers are familiar with GLP-1 medications, compared with 47% globally, suggesting the market is still at an early stage of adoption,” the report noted, “but uptake is expected to increase as key drugs approach patent expiry, which is likely to expand access and reduce costs over time.”
The study also revealed that 38% of South Africans are struggling either mentally or physically, significantly higher than the global average of 23%, with their main health concerns including body weight, stress levels, skin issues and anxiety.
Despite these challenges, though, there is a shift toward healthier living, and South Africa is among the top countries prioritising fresh cooking over processed foods.
“The early effects are already visible in how people shop,” said Nick Barrett, country manager for Worldpanel by Numerator in South Africa.
“Even at this early stage, we’re seeing clear shifts in behaviour. Consumers using these treatments are moving away from indulgent categories like snacks and confectionery towards protein, hydration and functional products.”
GLP-1 users are already buying fewer ready-made meals and sweets, instead opting for protein-rich foods, lighter meals and increased water consumption, the report noted.
See more from MedicalBrief archives:
Why obesity should be treated as a chronic disease in South Africa
SA sales of weight-loss drugs surge amid global rise in lawsuits
SAHPRA grants Mounjaro jab approval for weight loss